Breaking News
FONT-SIZE Plus   Neg
Share SHARE

Hospira Gets FDA Notice Following Inspection Of Rocky Mount Facility

Injectable drugs maker Hospira Inc. (HSP: Quote) said Tuesday that the U.S. Food and Drug Administration completed an inspection of the company's Rocky Mount facility in North Carolina and issued a Form 483 with 20 observations, three of which were designated as repeat observations.

Lake Forest, Illinois-based Hospira, a provider of injectable drugs and infusion technologies, said it is taking the matter seriously. The company warned that any actions by the FDA or the company in response to the inspection could impact its ability to increase supply of products to the market, raise its costs for remediation activities and also adversely impact its operations.

Hospira has been under review by the FDA for quality concerns at its medical device unit, leading to maintenance shutdowns and shortage of drugs. The Rocky Mount facility has been subject to an FDA warning letter since April 2010.

The FDA completed the inspection of the Rocky Mount facility on March 1, 2013 and issued the Form 483, which is used by the FDA to document and communicate concerns discovered by the agency during its inspections. A recipient of Form 483 should respond to the FDA, addressing each item, indicating agreement and either providing a timeline for correction or requesting clarification of what the FDA requires.

Hospira noted that a number of the observations deal with matters for which remediation was already underway but not yet complete or are matters previously self-identified for remediation by the company. Hospira said it will seek input from the FDA regarding the scope and timing of remediation efforts at the facility.

Further, Hospira said it will evaluate whether there will be any financial impact from this matter and will include any such impact in its 2013 earnings guidance that will be announced as part of its first-quarter 2013 earnings call.

In February, the FDA expanded an import ban on several of Hospira's products made in a Costa Rica plant. The agency had earlier issued an import ban on the company's Symbiq intravenous pump in November 2012.

Following the FDA ban, Hospira withdrew its financial outlook for fiscal 2013 that was provided by the company on February 13 along with the announcement of its financial results for the fourth quarter.

HSP closed Monday's trading at $29.77, up $0.32 on a volume of 1.79 million shares.

Register
To receive FREE breaking news email alerts for Hospira Inc and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
After reporting an unexpected drop in new orders for U.S. manufactured durable goods in the previous month, the Commerce Department released a report on Friday showing that durable goods orders rebounded by more than expected in the month of June. After showing a lack of direction throughout much of the previous session, stocks may move to the downside in early trading on Friday. The major index futures are currently pointing to a modestly lower open for the markets, with the Dow futures down by 23 points. British economic growth remained high as expected in the second quarter as a robust expansion in the dominant service sector, and industry completely offset the slight weakness in the construction sector. With the second quarter expansion, GDP returned to its pre-crisis level. Gross domestic product grew 0.8 percent sequentially in the second quarter, the same rate as seen in the first quarter.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.